M&As this week: Inspyr Therapeutics, Nissui Pharmaceutical


With the aim of strengthening its pipeline of drugs targeting cancer, inflammation and other conditions, Inspyr Therapeutics has agreed to acquire Lewis and Clark Pharmaceuticals.

Following the all-stock transaction, the target company’s shareholders will own 50% of the acquirer company’s common shares.

The acquirer company is a clinical-stage biotechnology company, whereas the target company is a biotechnology company.

"Nippon Suisan Kaisha’s subsidiary Nissui Pharmaceutical has reached an agreement to its pharmaceutical subsidiary company based in Yamanashi, Japan, to Senshukai."

Both companies involved in the transaction are based in the US.

Nippon Suisan Kaisha’s subsidiary Nissui Pharmaceutical has reached an agreement to its pharmaceutical subsidiary company based in Yamanashi, Japan, to Senshukai.

Also based in Japan, the acquirer company is engaged in mail-order business.